Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Wilkinson

Showing results (181-190 of 190) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 190 results.
Pharmacogenetics|February 18, 1999
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in CaucasiansG C Ibeanu, J Blaisdell, B I Ghanayem, et al.
Urologic Oncology|January 14, 2011
Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancerR Persad, C Fleming, H D Chern, et al.
Clinical Pharmacology and Therapeutics|September 1, 1990
Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoinD G May, C M Black, N J Olsen, et al.
Pharmacogenetics|January 1, 1995
The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factorsR A Branch, H D Chern, A Adedoyin, et al.
Clinical Pharmacology and Therapeutics|August 1, 1986
Encainide disposition in patients with chronic cirrhosisR H Bergstrand, T Wang, D M Roden, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoinR J Ferguson, S M De Morais, S Benhamou, et al.
Pharmaceutical Research|April 23, 1999
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoproteinR B Kim, C Wandel, B Leake, et al.
Pharmacogenetics|December 12, 2001
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentrationY S Lin, G F Lockwood, M A Graham, et al.
Clinical Pharmacology and Therapeutics|August 15, 2001
Identification of functionally variant MDR1 alleles among European Americans and African AmericansR B Kim, B F Leake, E F Choo, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasmaD W Haas, L A Clough, B W Johnson, et al.
Pageof 19

Showing results (181-190 of 190) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 190 results.
Pharmacogenetics|February 18, 1999
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in CaucasiansG C Ibeanu, J Blaisdell, B I Ghanayem, et al.
Urologic Oncology|January 14, 2011
Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancerR Persad, C Fleming, H D Chern, et al.
Clinical Pharmacology and Therapeutics|September 1, 1990
Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoinD G May, C M Black, N J Olsen, et al.
Pharmacogenetics|January 1, 1995
The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factorsR A Branch, H D Chern, A Adedoyin, et al.
Clinical Pharmacology and Therapeutics|August 1, 1986
Encainide disposition in patients with chronic cirrhosisR H Bergstrand, T Wang, D M Roden, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoinR J Ferguson, S M De Morais, S Benhamou, et al.
Pharmaceutical Research|April 23, 1999
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoproteinR B Kim, C Wandel, B Leake, et al.
Pharmacogenetics|December 12, 2001
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentrationY S Lin, G F Lockwood, M A Graham, et al.
Clinical Pharmacology and Therapeutics|August 15, 2001
Identification of functionally variant MDR1 alleles among European Americans and African AmericansR B Kim, B F Leake, E F Choo, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasmaD W Haas, L A Clough, B W Johnson, et al.
Pageof 19